UKRAINE – AbbVie has announced that all profits from its essential medicines sales in Russia will be donated to direct humanitarian relief efforts in Ukraine. AbbVie, along with Novartis and…
Read MoreTag: AbbVie
AbbVie’s Rinvoq debuts into gastroenterology space with FDA approval to include ulcerative colitis
USA – AbbVie has announced that the FDA has expanded Rinvoq (upadacitinib) approval to include the treatment of adults with moderate-to-severely active ulcerative colitis (UC) who have had insufficient response…
Read MoreAbbVie and Richter expand partnership to develop neuropsychiatric diseases therapies
USA – US pharma major AbbVie has again linked up with Hungary’s largest drugmaker Gedeon Richter in research, development, and marketing of new dopamine receptor modulators for the treatment of…
Read MoreAbbVie makes neuro drug connection with US$1 billion Syndesi Therapeutics acquisition
USA – AbbVie has expanded its neuropsychiatric and neurodegenerative portfolio with the US$1 billion acquisition of Belgium-based Syndesi Therapeutics. AbbVie will make an upfront payment of US$130 million to Syndesi…
Read MorePrivate Equity firms mull co-bidding for Novartis generics arm
SWITZERLAND – Two private equity giants are discussing launching a joint bid for Novartis’ generics unit, Bloomberg has reported. Novartis announced last year that it was conducting a strategic review…
Read MoreRoche looks to compete against Regeneron’s blockbuster with its newly approved vision drug
SWITZERLAND – Roche announced that it has received FDA approval for the first-ever bispecific antibody treatment for two common causes of vision loss, paving the way for a battle with…
Read MoreEli Lilly to invest US$1B in manufacturing facility in North Carolina
USA – Eli Lilly and Company has announced that it will invest more than US$1 billion in a new manufacturing facility in North Carolina. Eli Lilly’s new facility in Concord,…
Read MoreAbbVie, Pfizer’s JAK inhibitors get FDA clearance to treat atopic dermatitis
USA – The FDA has approved two once-daily, oral JAK inhibitors on for patients with moderate-to-severe atopic dermatitis whose disease is not well controlled with other systemic medications, including biologics,…
Read MoreSanofi in groundbreaking deal with ABL Bio to develop Parkinson’s disease drug
FRANCE – ABL Biotechnologies, a South Korean biotechnology firm, has signed a global licensing and exclusive collaboration agreement with Sanofi to develop and commercialize a new Parkinson’s disease therapy candidate.…
Read MoreUSFDA approves Sun Pharma’s generic Amphotericin B Liposome for injection
INDIA – Sun Pharmaceuticals Industries announced that one of its wholly-owned subsidiaries received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA)…
Read More